0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover1620.77%IV-64.58%PremiumJul 26, 2024Expiry Date7.29Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9351Delta0.0107Gamma1.44Leverage Ratio-0.4733Theta0.0001Rho1.34Eff Leverage0.0009Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet